Global PD-1 and PD-L1 Monoclonal Antibodies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 105

Published Date: 25 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Monoclonal Antibodies market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

According to the different tumor immune mechanisms, the most studied immunotherapy currently mainly includes cellular immunotherapy and immune checkpoint inhibitor therapy. Among them, the immune checkpoint inhibitor that can be used clinically has cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T lymphocyte-associated antigen 4). ' lymphocyte associated antigen-4, CTLA-4) and programmed cell death protein-1 (programmed cell death protein-1, PD-1)/programmed cell death-ligand 1 (programmed cell death-ligand 1, PD- L1). This report studies PD-1 and PD-L1 monoclonal antibodies.

The Global Info Research report includes an overview of the development of the PD-1 and PD-L1 Monoclonal Antibodies industry chain, the market status of Lung Cancer Treatment (PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody), Melanoma Treatment (PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PD-1 and PD-L1 Monoclonal Antibodies.

Regionally, the report analyzes the PD-1 and PD-L1 Monoclonal Antibodies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PD-1 and PD-L1 Monoclonal Antibodies market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the PD-1 and PD-L1 Monoclonal Antibodies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PD-1 and PD-L1 Monoclonal Antibodies industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PD-1 and PD-L1 Monoclonal Antibodies market.

Regional Analysis: The report involves examining the PD-1 and PD-L1 Monoclonal Antibodies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PD-1 and PD-L1 Monoclonal Antibodies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to PD-1 and PD-L1 Monoclonal Antibodies:
Company Analysis: Report covers individual PD-1 and PD-L1 Monoclonal Antibodies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PD-1 and PD-L1 Monoclonal Antibodies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer Treatment, Melanoma Treatment).

Technology Analysis: Report covers specific technologies relevant to PD-1 and PD-L1 Monoclonal Antibodies. It assesses the current state, advancements, and potential future developments in PD-1 and PD-L1 Monoclonal Antibodies areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PD-1 and PD-L1 Monoclonal Antibodies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
PD-1 and PD-L1 Monoclonal Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
PD-1 Monoclonal Antibody
PD-L1 Monoclonal Antibody

Market segment by Application
Lung Cancer Treatment
Melanoma Treatment
Bowel Cancer Treatment
Other

Market segment by players, this report covers
Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe PD-1 and PD-L1 Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-1 and PD-L1 Monoclonal Antibodies, with revenue, gross margin and global market share of PD-1 and PD-L1 Monoclonal Antibodies from 2019 to 2024.
Chapter 3, the PD-1 and PD-L1 Monoclonal Antibodies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and PD-1 and PD-L1 Monoclonal Antibodies market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Monoclonal Antibodies.
Chapter 13, to describe PD-1 and PD-L1 Monoclonal Antibodies research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of PD-1 and PD-L1 Monoclonal Antibodies
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of PD-1 and PD-L1 Monoclonal Antibodies by Type
        1.3.1 Overview: Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type in 2023
        1.3.3 PD-1 Monoclonal Antibody
        1.3.4 PD-L1 Monoclonal Antibody
    1.4 Global PD-1 and PD-L1 Monoclonal Antibodies Market by Application
        1.4.1 Overview: Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Lung Cancer Treatment
        1.4.3 Melanoma Treatment
        1.4.4 Bowel Cancer Treatment
        1.4.5 Other
    1.5 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size & Forecast
    1.6 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast by Region
        1.6.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region, (2019-2030)
        1.6.3 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2019-2030)
        1.6.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2019-2030)
        1.6.6 South America PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2019-2030)
        1.6.7 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Merck
        2.1.1 Merck Details
        2.1.2 Merck Major Business
        2.1.3 Merck PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.1.4 Merck PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Merck Recent Developments and Future Plans
    2.2 Bristol-Myers Squibb
        2.2.1 Bristol-Myers Squibb Details
        2.2.2 Bristol-Myers Squibb Major Business
        2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.3 Roche
        2.3.1 Roche Details
        2.3.2 Roche Major Business
        2.3.3 Roche PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.3.4 Roche PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Roche Recent Developments and Future Plans
    2.4 Pfizer
        2.4.1 Pfizer Details
        2.4.2 Pfizer Major Business
        2.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.4.4 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Pfizer Recent Developments and Future Plans
    2.5 Astrazeneca
        2.5.1 Astrazeneca Details
        2.5.2 Astrazeneca Major Business
        2.5.3 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.5.4 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Astrazeneca Recent Developments and Future Plans
    2.6 Novartis
        2.6.1 Novartis Details
        2.6.2 Novartis Major Business
        2.6.3 Novartis PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.6.4 Novartis PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Novartis Recent Developments and Future Plans
    2.7 Biocad
        2.7.1 Biocad Details
        2.7.2 Biocad Major Business
        2.7.3 Biocad PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.7.4 Biocad PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Biocad Recent Developments and Future Plans
    2.8 Sanofi/Regeneron Pharmaceuticals
        2.8.1 Sanofi/Regeneron Pharmaceuticals Details
        2.8.2 Sanofi/Regeneron Pharmaceuticals Major Business
        2.8.3 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.8.4 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Sanofi/Regeneron Pharmaceuticals Recent Developments and Future Plans
    2.9 Beigene
        2.9.1 Beigene Details
        2.9.2 Beigene Major Business
        2.9.3 Beigene PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.9.4 Beigene PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Beigene Recent Developments and Future Plans
    2.10 Jiangsu Hengrui Pharmaceuticals
        2.10.1 Jiangsu Hengrui Pharmaceuticals Details
        2.10.2 Jiangsu Hengrui Pharmaceuticals Major Business
        2.10.3 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.10.4 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments and Future Plans
    2.11 Innovent Biologics, Inc.
        2.11.1 Innovent Biologics, Inc. Details
        2.11.2 Innovent Biologics, Inc. Major Business
        2.11.3 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
        2.11.4 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 Innovent Biologics, Inc. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of PD-1 and PD-L1 Monoclonal Antibodies by Company Revenue
        3.2.2 Top 3 PD-1 and PD-L1 Monoclonal Antibodies Players Market Share in 2023
        3.2.3 Top 6 PD-1 and PD-L1 Monoclonal Antibodies Players Market Share in 2023
    3.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Overall Company Footprint Analysis
        3.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market: Region Footprint
        3.3.2 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
        3.3.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value and Market Share by Type (2019-2024)
    4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2024)
    5.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Forecast by Application (2025-2030)

6 North America
    6.1 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2030)
    6.2 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2030)
    6.3 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
        6.3.1 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2030)
        6.3.2 United States PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        6.3.3 Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        6.3.4 Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2030)
    7.2 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2030)
    7.3 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
        7.3.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2030)
        7.3.2 Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        7.3.3 France PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        7.3.5 Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        7.3.6 Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region
        8.3.1 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2019-2030)
        8.3.2 China PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        8.3.3 Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        8.3.4 South Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        8.3.5 India PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        8.3.7 Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)

9 South America
    9.1 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2030)
    9.2 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2030)
    9.3 South America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
        9.3.1 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2030)
        9.3.2 Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        9.3.3 Argentina PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
        10.3.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2030)
        10.3.2 Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)
        10.3.4 UAE PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
    11.2 PD-1 and PD-L1 Monoclonal Antibodies Market Restraints
    11.3 PD-1 and PD-L1 Monoclonal Antibodies Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 PD-1 and PD-L1 Monoclonal Antibodies Industry Chain
    12.2 PD-1 and PD-L1 Monoclonal Antibodies Upstream Analysis
    12.3 PD-1 and PD-L1 Monoclonal Antibodies Midstream Analysis
    12.4 PD-1 and PD-L1 Monoclonal Antibodies Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
    Table 4. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
    Table 5. Merck Company Information, Head Office, and Major Competitors
    Table 6. Merck Major Business
    Table 7. Merck PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 8. Merck PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 9. Merck Recent Developments and Future Plans
    Table 10. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
    Table 11. Bristol-Myers Squibb Major Business
    Table 12. Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 13. Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 14. Bristol-Myers Squibb Recent Developments and Future Plans
    Table 15. Roche Company Information, Head Office, and Major Competitors
    Table 16. Roche Major Business
    Table 17. Roche PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 18. Roche PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 19. Roche Recent Developments and Future Plans
    Table 20. Pfizer Company Information, Head Office, and Major Competitors
    Table 21. Pfizer Major Business
    Table 22. Pfizer PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 23. Pfizer PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 24. Pfizer Recent Developments and Future Plans
    Table 25. Astrazeneca Company Information, Head Office, and Major Competitors
    Table 26. Astrazeneca Major Business
    Table 27. Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 28. Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 29. Astrazeneca Recent Developments and Future Plans
    Table 30. Novartis Company Information, Head Office, and Major Competitors
    Table 31. Novartis Major Business
    Table 32. Novartis PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 33. Novartis PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 34. Novartis Recent Developments and Future Plans
    Table 35. Biocad Company Information, Head Office, and Major Competitors
    Table 36. Biocad Major Business
    Table 37. Biocad PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 38. Biocad PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 39. Biocad Recent Developments and Future Plans
    Table 40. Sanofi/Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 41. Sanofi/Regeneron Pharmaceuticals Major Business
    Table 42. Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 43. Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 44. Sanofi/Regeneron Pharmaceuticals Recent Developments and Future Plans
    Table 45. Beigene Company Information, Head Office, and Major Competitors
    Table 46. Beigene Major Business
    Table 47. Beigene PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 48. Beigene PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 49. Beigene Recent Developments and Future Plans
    Table 50. Jiangsu Hengrui Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 51. Jiangsu Hengrui Pharmaceuticals Major Business
    Table 52. Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 53. Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 54. Jiangsu Hengrui Pharmaceuticals Recent Developments and Future Plans
    Table 55. Innovent Biologics, Inc. Company Information, Head Office, and Major Competitors
    Table 56. Innovent Biologics, Inc. Major Business
    Table 57. Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    Table 58. Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 59. Innovent Biologics, Inc. Recent Developments and Future Plans
    Table 60. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue (USD Million) by Players (2019-2024)
    Table 61. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Share by Players (2019-2024)
    Table 62. Breakdown of PD-1 and PD-L1 Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 63. Market Position of Players in PD-1 and PD-L1 Monoclonal Antibodies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
    Table 64. Head Office of Key PD-1 and PD-L1 Monoclonal Antibodies Players
    Table 65. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
    Table 66. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
    Table 67. PD-1 and PD-L1 Monoclonal Antibodies New Market Entrants and Barriers to Market Entry
    Table 68. PD-1 and PD-L1 Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations
    Table 69. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (USD Million) by Type (2019-2024)
    Table 70. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Share by Type (2019-2024)
    Table 71. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Type (2025-2030)
    Table 72. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024)
    Table 73. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Application (2025-2030)
    Table 74. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
    Table 75. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
    Table 76. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
    Table 77. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
    Table 78. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
    Table 79. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
    Table 80. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
    Table 81. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
    Table 82. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
    Table 83. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
    Table 84. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
    Table 85. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
    Table 86. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
    Table 87. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
    Table 88. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
    Table 89. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
    Table 90. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
    Table 91. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
    Table 92. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
    Table 93. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
    Table 94. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
    Table 95. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
    Table 96. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
    Table 97. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
    Table 98. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
    Table 99. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
    Table 100. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
    Table 101. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
    Table 102. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
    Table 103. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
    Table 104. PD-1 and PD-L1 Monoclonal Antibodies Raw Material
    Table 105. Key Suppliers of PD-1 and PD-L1 Monoclonal Antibodies Raw Materials
List of Figures
    Figure 1. PD-1 and PD-L1 Monoclonal Antibodies Picture
    Figure 2. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type in 2023
    Figure 4. PD-1 Monoclonal Antibody
    Figure 5. PD-L1 Monoclonal Antibody
    Figure 6. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 7. PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application in 2023
    Figure 8. Lung Cancer Treatment Picture
    Figure 9. Melanoma Treatment Picture
    Figure 10. Bowel Cancer Treatment Picture
    Figure 11. Other Picture
    Figure 12. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 13. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 14. Global Market PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
    Figure 15. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
    Figure 16. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Region in 2023
    Figure 17. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 18. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 19. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 20. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 21. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 22. Global PD-1 and PD-L1 Monoclonal Antibodies Revenue Share by Players in 2023
    Figure 23. PD-1 and PD-L1 Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
    Figure 24. Global Top 3 Players PD-1 and PD-L1 Monoclonal Antibodies Market Share in 2023
    Figure 25. Global Top 6 Players PD-1 and PD-L1 Monoclonal Antibodies Market Share in 2023
    Figure 26. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Share by Type (2019-2024)
    Figure 27. Global PD-1 and PD-L1 Monoclonal Antibodies Market Share Forecast by Type (2025-2030)
    Figure 28. Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Share by Application (2019-2024)
    Figure 29. Global PD-1 and PD-L1 Monoclonal Antibodies Market Share Forecast by Application (2025-2030)
    Figure 30. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
    Figure 31. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
    Figure 32. North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
    Figure 33. United States PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 34. Canada PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 35. Mexico PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 36. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
    Figure 37. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
    Figure 38. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
    Figure 39. Germany PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 40. France PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 41. United Kingdom PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 42. Russia PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 43. Italy PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 44. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
    Figure 45. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
    Figure 46. Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
    Figure 47. China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 48. Japan PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 49. South Korea PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 50. India PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 51. Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 52. Australia PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 53. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
    Figure 54. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
    Figure 55. South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
    Figure 56. Brazil PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 57. Argentina PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 58. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
    Figure 59. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
    Figure 60. Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
    Figure 61. Turkey PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 62. Saudi Arabia PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 63. UAE PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
    Figure 64. PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
    Figure 65. PD-1 and PD-L1 Monoclonal Antibodies Market Restraints
    Figure 66. PD-1 and PD-L1 Monoclonal Antibodies Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Monoclonal Antibodies in 2023
    Figure 69. Manufacturing Process Analysis of PD-1 and PD-L1 Monoclonal Antibodies
    Figure 70. PD-1 and PD-L1 Monoclonal Antibodies Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.

Related Reports

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 03 Dec 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Monoclonal Antibodies market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029

Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029

date 03 Dec 2023

date Pharma & Healthcare

The global PD-1 and PD-L1 Monoclonal Antibodies market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Product Tags

PD-1 and PD-L1 Monoclonal Antibodies

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>